Valion Bio Stock (NASDAQ:VBIO)

Revenue Financials Chart Transcripts

Previous Close

$0.16

52W Range

$0.11 - $3.46

50D Avg

$0.42

200D Avg

$1.05

Market Cap

$556.61K

Avg Vol (3M)

$6.73M

Beta

1.83

Div Yield

-

VBIO Company Profile

Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

52

IPO Date

Nov 11, 2021

Website

VBIO Performance

VBIO Financial Summary

	Mar 21	Mar 20	Mar 19
Revenue	-	-	-
Operating Income	$-2.34M	$-3.69M	$-4.57M
Net Income	$-880.85K	$-4.37M	$-20.14M
EBITDA	$-880.85K	$-3.69M	$-4.43M
Basic EPS	$-0.02	$-0.09	$-0.61
Diluted EPS	$-0.02	$-0.09	$-0.61

Fiscal year ends in Mar 21 | Currency in USD

Latest Earnings Call Transcripts

Q3 25Nov 14, 25 | 4:30 PM

Q2 25Aug 14, 25 | 4:30 PM